Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPediatrics/NeonatologyCareSource Georgia iNO Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentCareSource GeorgiaPolicy MP-MM-1321

    Inhaled Nitric Oxide

    Customize your policy alerts

    Sign up for CareSource Georgia Policy MP-MM-1321 alerts

    Get alerted when Policy MP-MM-1321 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and appropriate use of inhaled nitric oxide (iNO) for neonates, children, and adults in specified respiratory and pulmonary hypertension settings. It applies to CareSource Marketplace plans in Georgia, Ohio, and West Virginia.

    Policy Summary
    PayerCareSource Georgia
    PolicyInhaled Nitric Oxide
    Policy CodePolicy MP-MM-1321
    Change TypeAnnual reviewevidence and reference maintenance
    Effective DateDecember 1, 2026
    Last ReviewAug 26, 2026
    Next Review DateNot specified
    Key ActionSubmit medical record documentation supporting continued iNO medical necessity when therapy exceeds 3 days.
    SourceLink
    POLICY UPDATE CHANGES

    The policy history records updates to the background, definitions, and selected clinical sections, including an expanded definition of bronchopulmonary dysplasia.

    ≥34 weeksMinimum corrected gestational age for covered initiation
    3 daysReview threshold for continued iNO use
    4Medically appropriate clinical situations
    13Not medically necessary indications

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    GA, OH, WVApplicable Marketplace states

    Medical Necessity Criteria

    Initial therapy for near-term and term infants

    Initiation of iNO is medically necessary for near-term and term infants when ALL of the following conditions are present.

    Neonatal initiation criteria

    • The infant has hypoxic respiratory failure or evidence of persistent pulmonary hypertension and is near-term or term.≥34 weeks corrected gestational age
    • Conventional therapies, such as mechanical ventilation, administration of high concentrations of oxygen (80–100%), high-frequency oscillatory ventilation, induction of respiratory alkalosis, neuromuscular blockade, and sedation, have failed or are expected to fail.
    • The infant does not have ductal-dependent congenital heart disease.
    • There is evidence of PPHN from echocardiographic findings, right-heart catheterization, or abnormal oxygen index or arterial blood gases, and the findings are not related to another medical condition.

    Other medically appropriate uses

    iNO is medically appropriate when ANY of the following clinical conditions applies.

    Appropriate clinical conditions

    • Postoperative management of a neonate ≥34 weeks corrected gestational age after repair of congenital heart disease with evidence of pulmonary hypertension.≥34 weeks corrected gestational age
    • Postoperative management following pediatric heart or lung surgery with evidence of pulmonary hypertension.
    • Management of pulmonary hypertension during a heart catheterization to determine pulmonary vasoreactivity.
    • Management of BPD-related pulmonary hypertension during an acute crisis.

      Patients with chronic pulmonary hypertension related to BPD should be transitioned to enteral therapy when the acute crisis improves.

    Continuation therapy

    Continued iNO use beyond 3 days requires medical necessity review.

    Continuation beyond 3 days

    • Medical record documentation supports continued use after 3 days.>3 days
    • If there is a lack of a positive response to therapy with inability to wean oxygen and/or iNO after 3 days, discontinuation of iNO therapy should be considered.

    iNO is not medically necessary for congenital diaphragmatic hernia, acute bronchiolitis, bronchopulmonary dysplasia, acute pulmonary embolism, acute respiratory distress syndrome, acute lung injury, lung transplantation, liver transplantation, pulmonary fibrosis, hemorrhagic shock, pneumonectomy following trauma, cystic fibrosis, or malaria.

    Documentation and Review Requirements

    Documentation Required

    Review Required After 3 Days

    For iNO therapy continuing beyond 3 days, submit the medical record for medical necessity review and document the clinical rationale for extended treatment.

    • Required when therapy exceeds 3 days.
    • Include supporting medical records and evidence supporting continued use.
    Documentation Required

    Document Initial Neonatal Medical Necessity

    Before initiating iNO for a near-term (≥ 34 weeks corrected gestational age) or term infant, document hypoxic respiratory failure or evidence of PPHN and that all initiation requirements are met.

    • Conventional therapies—including mechanical ventilation, 80–100% oxygen, HFOV, induction of respiratory alkalosis, neuromuscular blockade, and sedation—have failed or are expected to fail.
    • There is no ductal-dependent congenital heart disease.
    • PPHN is supported by echocardiography, right-heart catheterization, or abnormal oxygen index/arterial blood gases not attributable to another medical condition.

    Clinical Background

    Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator that relaxes pulmonary vascular and bronchial smooth muscle. By reducing pulmonary vascular resistance and intrapulmonary shunting, it can improve arterial oxygenation. iNO is used with ventilatory support for hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn in term and near-term infants, and for pulmonary hypertension in selected postoperative and acute-crisis settings.

    Key Clinical Definitions

    Bronchopulmonary dysplasia (BPD)
    ConditionA chronic lung disease in premature infants.
    Clinical characteristicsMarked by impaired lung development or injury, with ongoing need for oxygen or respiratory support at 36 weeks corrected gestational age.
    Radiographic findingRadiographic signs of parenchymal lung disease are present.
    Corrected gestational age
    DefinitionGestational age at birth plus the number of weeks of age.
    CalculationCorrected gestational age = gestational age at birth + weeks of age.
    Example
    Policy Summary
    PayerCareSource Georgia
    PolicyInhaled Nitric Oxide
    Policy CodePolicy MP-MM-1321
    Change TypeAnnual reviewevidence and reference maintenance
    Effective DateDecember 1, 2026
    Last ReviewAug 26, 2026
    Next Review DateNot specified
    Key ActionSubmit medical record documentation supporting continued iNO medical necessity when therapy exceeds 3 days.
    SourceLink
    On This Page
    Medical Necessity CriteriaDocumentation and Review RequirementsClinical BackgroundKey Clinical Definitions
    Documentation Required

    Support Continued Use

    For continued iNO use, maintain records demonstrating ongoing medical necessity and the patient’s response to therapy, including the clinical basis for inability to wean oxygen and/or iNO when applicable.

    • Document response to treatment and the rationale for continuing therapy.
    • Include updated clinical findings and supporting medical records.
    Denial Risk

    Listed Non-Covered Indications

    iNO is not medically necessary for the following indications; document the diagnosis and clinical rationale carefully because treatment for these conditions is subject to non-coverage.

    • Congenital diaphragmatic hernia
    • Acute bronchiolitis
    • Bronchopulmonary dysplasia
    • Acute pulmonary embolism
    • Acute respiratory distress syndrome
    • Acute lung injury
    • Lung transplantation
    • Liver transplantation
    • Pulmonary fibrosis
    • Hemorrhagic shock
    • Pneumonectomy post trauma
    • Cystic fibrosis
    • Malaria
    Denial Risk

    Failure to Meet Initiation Criteria

    If the neonatal initiation criteria are not met, document the unmet criterion and the clinical rationale for treatment; coverage is not supported when the required medical-necessity conditions are absent.

    • Applies to near-term (≥ 34 weeks corrected gestational age) and term infants treated for hypoxic respiratory failure or PPHN.
    • Coverage criteria require failure or expected failure of conventional therapies, absence of ductal-dependent congenital heart disease, and qualifying evidence of PPHN.
    • An unsupported indication or missing documentation may result in non-coverage.
    Denial Risk

    Unjustified Treatment Beyond 3 Days

    When treatment extends beyond 3 days without a positive response, including inability to wean oxygen and/or iNO, reassess medical necessity and consider discontinuing iNO therapy.

    • Document the response—or lack of response—to therapy after 3 days.
    • Record the clinical rationale for continuation if treatment is not discontinued.
    24 weeks gestational age at birth + 10 weeks of age = 34 weeks corrected gestational age.
    Extracorporeal membrane oxygenation (ECMO)
    DefinitionTemporary support of heart and lung function by partial cardiopulmonary bypass.
    Maximum supportPartial cardiopulmonary bypass can provide up to 75% of cardiac output.
    PurposeUsed for reversible cardiopulmonary failure from pulmonary, cardiac, or other disease.
    Hypoxic respiratory failure
    DefinitionA serious condition that develops when the lungs cannot provide sufficient oxygen into the blood.
    EffectInsufficient oxygen in the blood prevents oxygen from reaching the tissues of the body.
    Clinical contextThe condition is assessed in the policy together with persistent pulmonary hypertension of the newborn.
    Nitric oxide (NO)
    Chemical nameNitric oxide is also called nitrogen monoxide.
    PropertiesA colorless, lipophilic gas formed by the oxidation of nitrogen.
    Physiologic signaling rolePerforms important chemical signaling functions in humans and other animals.
    Medical useHas various applications in medicine.
    Oxygen index (OI)
    PurposeUsed to assess the severity of hypoxic respiratory failure and persistent pulmonary hypertension of the newborn.
    CalculationOI = mean airway pressure × FiO2 × 100 ÷ partial pressure of arterial oxygen.
    InputsThe calculation uses mean airway pressure, FiO2, and partial pressure of arterial oxygen.
    Persistent pulmonary hypertension of the newborn (PPHN)
    DefinitionFailure of the pulmonary vasculature to relax at birth.
    Hemodynamic effectThis results in increased pulmonary arterial pressure and pulmonary vascular resistance.
    PathophysiologyThe increased pressure and resistance lead to shunting of deoxygenated blood into the systemic circulation.